Last reviewed · How we verify

NCT04084379

Implementation Strategy of Bio-molecular Techniques for Early Diagnose of Congenital Syphilis and Chagas Diseases

Status unknown Last updated 1 March 2023
What this trial tests

trial in Chagas Disease in 560 participants. Status unknown.

Timeline
1 July 2019
Primary endpoint
30 December 2023
1 September 2024

Quick facts

Lead sponsorHospital de Niños R. Gutierrez de Buenos Aires
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment560
Start date1 July 2019
Primary completion30 December 2023
Estimated completion1 September 2024
Sites1 location across Argentina

Conditions studied

Sponsor

Hospital de Niños R. Gutierrez de Buenos Aires

Who can join

Adults 1 Day to 18, any sex, with Chagas Disease or Syphilis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Chagas disease and syphilis are considered a mayor public health problem worldwide. Both pathologies affect socio-economic vulnerable population and they are both transmitted congenitally, causing an alarming increasing number of infected newborns. The current diagnostic methods for these diseases are based on serology follow-up until 8 to 10 months from birth, which considering the population usually involved and their scarce resources, usually translates in loosing continuity in their controls and follow-up. Chagas prevalence in pregnant women is 4% with an incidence of Congenital Chagas disease of 1500 annual cases. From those, only 1 third are diagnosed. In the investigators and other authors experience, the detection of DNA of Trypanosoma cruzi by PCR shows an elevation of parasitemia at birth, with a peak at the first month of life. Syphilis is a re-emergent pathology, preventable and curable when diagnose is achieved early at the beginning of pregnancy.. The cost-effectiveness of performing screening for this infection is widely demonstrated, preventing high morbi-mortality for children when applied to pregnant women. For both syphilis and Chagas diagnosis, there are some studies comparing PCR follow-up with conventional serology, but none were validated and there is still need to bring more evidence in order to modify current practice. The investigators propose a sequential study of PCR for Tryipanosoma cruzi and Treponema pallidum from birth, believing this will increase sensitivity of congenital Chagas and syphilis diagnose and improve follow-up of these patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Congenital syphilis in Argentina: Experience in a pediatric hospital.
    Garcia LN, Destito Solján A, Moroni S, Falk N, et al · · 2021 · cited 8× · PMID 33406082 · DOI 10.1371/journal.pntd.0009010

Verify or expand the search:

Other recruiting trials for Chagas Disease

Currently open trials in the same condition.

Other Hospital de Niños R. Gutierrez de Buenos Aires trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04084379.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing